Psychiatry Research
Volume 150, Issue 1 , Pages 61-69 , 28 February 2007

Lower levels of whole blood serotonin in obsessive-compulsive disorder and in schizophrenia with obsessive-compulsive symptoms

  • Ning Ma

      Affiliations

    • Mental Health Institute, the Second Hospital of Xiangya Medical College, Central South University, Changsha 41001, Hunan, China
    • ,
  • Li-wen Tan

      Affiliations

    • Mental Health Institute, the Second Hospital of Xiangya Medical College, Central South University, Changsha 41001, Hunan, China
    • ,
  • Qiang Wang

      Affiliations

    • Clinical Laboratory, Zhejiang Hospital, Hangzhou, Zhejiang, China
    • ,
  • Ze-xuan Li

      Affiliations

    • Mental Health Institute, the Second Hospital of Xiangya Medical College, Central South University, Changsha 41001, Hunan, China
    • ,
  • Ling-jiang Li

      Affiliations

    • Mental Health Institute, the Second Hospital of Xiangya Medical College, Central South University, Changsha 41001, Hunan, China
    • Corresponding Author InformationCorresponding author. Tel./fax: +86 731 5360086.

Received 13 May 2005 ,Revised 13 September 2005 ,Accepted 9 October 2005.

References 

  1. Ackenheil M, Blatt B, Lampart C. Effect of clozapine on 5-HIAA excretion in urine and CSF of psychotic patients and on serotonin metabolism in rat brain. Acta Vitaminologica et Enzymologica. 1975;29:79–84
  2. American Psychiatric Association . Diagnostic and Statistical Manual of Mental Disorders. 4th ed.. Washington, DC: APA; 1994;
  3. Attiullah N, Eisen JL, Rasmussen SA. Clinical features of obsessive-compulsive disorder. Psychiatric Clinics of North America. 2000;23:469–491
  4. Aymard N, Viala A, Baldacci C, Smagghe PO, Vacheron MN, Caroli F. Pharmacoclinical strategy in neuroleptic resistant schizophrenic patients treated by clozapine: clinical evolution, concentration of plasma and red blood cell clozapine and desmethylclozapine, whole blood serotonin and tryptophan. Progress in Neuro-psychopharmacology & Biological Psychiatry. 1999;23:25–41
  5. Baker RW, Chengappa KN, Baird JW, Steingard S, Christ MA, Schooler NR. Emergence of obsessive compulsive symptoms during treatment with clozapine. Journal of Clinical Psychiatry. 1992;53:439–442
  6. Banki CM. 5-Hydroxytryptamine content of the whole blood in psychiatric illness and alcoholism. Acta Psychiatica Scandinavica. 1978;57:232–238
  7. Banki CM. Alterations of cerebrospinal fluid 5-hydroxyindoleacetic acid, and total blood serotonin content during clozapine treatment. Psychopharmacology (Berlin). 1978;56:195–198
  8. Benkelfat C, Murphy DL, Zohar J, Hill JL, Grover G, Insel TR. Clomipramine in obsessive-compulsive disorder. Further evidence for a serotonergic mechanism of action. Archives of General Psychiatry. 1989;46:23–28
  9. Bermanzohn PC, Porto L, Arlow PB, Pollack S, Stronger R, Siris SG. Hierarchical diagnosis in chronic schizophrenia: a clinical study of co-occurring syndromes. Schizophrenia Bulletin. 2000;26:517–525
  10. Borcsiczky D, Tekes K, Tarcali J, Meszaros Z, Faludi G, Mathe M, et al. Platelet rich plasma serotonin content in patients suffering from different psychiatric disorders. Acta Physiologica Hungarica. 1996;84:403–404
  11. Braunig P, Rao ML, Fimmers R. Blood serotonin levels in suicidal schizophrenic patients. Acta Psychiatrica Scandinavica. 1989;79:186–189
  12. Breier A. Serotonin, schizophrenia and antipsychotic drug action. Schizophrenia Research. 1995;14:187–202
  13. Byerly M, Goodman W, Acholonu W, Bugno R, Rush AJ. Obsessive compulsive symptoms in schizophrenia: frequency and clinical features. Schizophrenia Research. 2005;76:309–316
  14. Camarena B, Aguilar A, Loyzaga C, Nicolini H. A family-based association study of the 5-HT-1Dbeta receptor gene in obsessive-compulsive disorder. International Journal of Neuropsychopharmacology. 2004;7:49–53
  15. Cath DC, Spinhoven P, Landman AD, van Kempen GM. Psychopathology and personality characteristics in relation to blood serotonin in Tourette's syndrome and obsessive-compulsive disorder. Journal of Psychopharmacology. 2001;15:111–119
  16. Chabane N, Millet B, Delorme R, Lichtermann D, Mathieu F, Laplanche JL, et al. Lack of evidence for association between serotonin transporter gene (5-HTTLPR) and obsessive-compulsive disorder by case control and family association study in humans. Neuroscience Letters. 2004;363:154–156
  17. Chen Jue, Xiao Ze-ping, Lin Zhi-guang, Wang Ke-xuan. Platelet serotonin, plasma prolactin and dexa methasone suppression test in patients with obseeive compulsive disorder. Chinese Journal of Psychiatry. 2004;37:14–17
  18. de Haan L, Linszen DH, Gorsira R. Clozapine and obsessions in patients with recent-onset schizophrenia and other psychotic disorders. Journal of Clinical Psychiatry. 1999;60:364–365
  19. DeLisi LE, Neckers LM, Weinberger DR, Wyatt RJ. Increased whole blood serotonin concentrations in chronic schizophrenic patients. Archives of General Psychiatry. 1981;38:647–650
  20. Delorme R, Chabane N, Callebert J, Falissard B, Mouren-Simeoni MC, Rouillon F, et al. Platelet serotonergic predictors of clinical improvement in obsessive compulsive disorder. Journal of Clinical Psychopharmacology. 2004;24:18–23
  21. Di Bella D, Cavallini MC, Bellodi L. No association between obsessive-compulsive disorder and the 4-HT1Dbeta receptor gene. American Journal of Psychiatry. 2002;159:1783–1785
  22. Dursun SM, Szemis A, Andrews H, Whitaker P, Reveley MA. Effects of clozapine and typical antipsychotic drugs on plasma 5-HT turnover and impulsivity in patients with schizophrenia: a cross-sectional study. Journal of Psychiatry and Neuroscience. 2000;25:347–352
  23. Eales MJ, Layeni AO. Exacerbation of obsessive-compulsive symptoms associated with clozapine. British Journal of Psychiatry. 1994;164:687–688
  24. Fabisch K, Fabisch H, Langs G, Huber HP, Zapotoczky HG. Incidence of obsessive-compulsive phenomena in the course of acute schizophrenia and schizoaffective disorder. European Journal of Psychiatry. 2001;16:336–341
  25. Flament MF, Rapoport JL, Murphy DL, Berg CJ, Lake CR. Biochemical changes during clomipramine treatment of childhood obsessive-compulsive disorder. Archives of General Psychiatry. 1987;44:219–225
  26. Galvez-Buccollini JA, Fiestas F, Herrera P, Vega-Dienstmaier JM, Guimas B, Mazzotti G. Obsessive-compulsive symptoms in schizophrenia during treatment with clozapine and conventional antipsychotic drugs. Actas Españolas de Psiquiatría. 2004;32:211–215
  27. Garelis E, Gillin JC, Wyatt RJ, Neff N. Elevated blood serotonin concentrations in unmedicated chronic schizophrenic patients: a preliminary study. American Journal of Psychiatry. 1975;132:184–186
  28. Goodman W, Price H, Rasmussen S, Blake JB. The Yale Brown Obsessive Compulsive Scale (Y-BOCS): Part I. Development, use, and reliability. Archives of General Psychiatry. 1989;46:1006–1011
  29. Greist J, Chouinard G, DuBoff E, Halaris A, Kim SW, Koran L, et al. Double-blind parallel comparison of three dosages of sertraline and placebo in outpatients with obsessive-compulsive disorder. Archives of General Psychiatry. 1995;52:289–295
  30. Hanna GL, Yuwiler A, Cantwell DP. Whole blood serotonin in juvenile obsessive-compulsive disorder. Biological Psychiatry. 1991;29:738–744
  31. Insel TR, Mueller EA, Alterman I, Linnoila M, Murphy DL. Obsessive-compulsive disorder and serotonin: is there a connection?. Biological Psychiatry. 1985;20:1174–1188
  32. Jackman H, Luchins D, Meltzer HY. Platelet serotonin levels in schizophrenia: relationship to race and psychopathology. Biological Psychiatry. 1983;18:887–902
  33. Jakovljevic M, Muck-Seler D, Pivac N, Ljubicic D, Bujas M, Dodig G. Seasonal influence on platelet 5-HT levels in patients with recurrent major depression and schizophrenia. Biological Psychiatry. 1997;41:1028–1034
  34. Joseph MH, Owen F, Baker HF, Bourne RC. Platelet serotonin concentration and monoamine oxidase activity in unmedicated chronic schizophrenic and in schizoaffective patients. Psychological Medicine. 1977;7:159–162
  35. Katz RJ, DeVeaugh-Geiss J, Landau P. Clomipramine in obsessive-compulsive disorder. Biological Psychiatry. 1990;28:401–414
  36. Kolakowska T, Molyneux SG. Platelet serotonin concentration in schizophrenic patients. American Journal of Psychiatry. 1987;144:232–234
  37. LaPorta LD. More on obsessive-compulsive symptoms and clozapine. Journal of Clinical Psychiatry. 1994;55:312
  38. Lesch KP, Wolozin BL, Murphy DL, Riederer P. Primary structure of the human platelet serotonin uptake site: identity with the brain serotonin transporter. Journal of Neurochemistry. 1993;60:2319–2322
  39. Lucey JV, Butcher G, Clare AW, Dinan TG. Buspirone induced prolactin responses in obsessive-compulsive disorder (OCD): is OCD a 5-HT2 receptor disorder?. International Clinical Psychopharmacology. 1992;7:45–49
  40. MacCabe JH, Travis M. Clozapine-induced obsessive-compulsive symptoms. Progress in Neuro-psychopharmacology & Biological Psychiatry. 2004;28:1209
  41. Markianos M, Botsis A, Arvanitis Y. Biogenic amine metabolites in plasma of drug-naive schizophrenic patients: associations with symptomatology. Biological Psychiatry. 1992;32:288–292
  42. Markianos M, Hatzimanolis J, Lykouras L, Christodoulou GN. Prolactin responses to acute clomipramine and haloperidol of male schizophrenic patients in a drug-free state and after treatment with clozapine or with olanzapine. Schizophrenia Research. 2002;56:11–17
  43. Muck-Seler D, Jakovljevic M, Deanovic Z. Time course of schizophrenia and platelet 5-HT level. Biological Psychiatry. 1988;23:243–251
  44. Muck-Seler D, Jakovljevic M, Deanovic Z. Platelet serotonin in subtypes of schizophrenia and unipolar depression. Psychiatry Research. 1991;38:105–113
  45. Muck-Seler D, Bujas M, Ljubic-Thibal V, Jakovljevic M. Effect of age on platelet 5-HT concentrations in healthy controls, depressed and schizophrenic patients. Neuropsychobiology. 1996;34:201–203
  46. Muck-Seler D, Pivac N, Jakovljevic M. Sex differences, season of birth and platelet 5-HT levels in schizophrenic patients. Journal of Neural Transmission. 1999;106:337–347
  47. Muck-Seler D, Pivac N, Jakovljevic M, Brzovic Z. Platelet serotonin, plasma cortisol, and dexamethasone suppression test in schizophrenic patients. Biological Psychiatry. 1999;45:1433–1439
  48. Muck-Seler D, Pivac N, Mustapic M, Crncevic Z, Jakovljevic M, Sagud M. Platelet serotonin and plasma prolactin and cortisol in healthy, depressed and schizophrenic women. Psychiatry Research. 2004;127:217–226
  49. Oades RD, Ropcke B, Eggers C. Monoamine activity reflected in urine of young patients with obsessive compulsive disorder, psychosis with and without reality distortion and healthy subjects: an explorative analysis. Journal of Neural Transmission. General Section. 1994;96:143–159
  50. Oades RD, Klimke A, Henning U, Rao ML. Relations of clinical features, subgroups and medication to serum monoamines in schizophrenia. Human Psychopharmacology. 2002;17:15–27
  51. Oades RD, Roepcke B, Henning U, Klimke A. Neuropsychological measures of attention and memory function in schizophrenia: relationships with symptom dimensions and serum monoamine activity. Behavioral and Brain Functions. 2005;1:14
  52. Ongur D, Goff DC. Obsessive-compulsive symptoms in schizophrenia: associated clinical features, cognitive function and medication status. Schizophrenia Research. 2005;75:349–362
  53. Piccinelli M, Pini S, Bellantuono C, Wilkinson G. Efficacy of drug treatment in obsessive-compulsive disorder. A meta-analytic review. British Journal of Psychiatry. 1995;166:424–443
  54. Poyurovsky M, Fuchs C, Weizman A. Obsessive-compulsive disorder in patients with first-episode schizophrenia. American Journal of Psychiatry. 1999;156:1998–2000
  55. Poyurovsky M, Hramenkov S, Isakov V, Rauchverger B, Modai I, Schneidman M, et al. Obsessive-compulsive disorder in hospitalized patients with chronic schizophrenia. Psychiatry Research. 2001;102:49–57
  56. Poyurovsky M, Kriss V, Weisman G, Faragian S, Kurs R, Schneidman M, et al. Comparison of clinical characteristics and comorbidity in schizophrenia patients with and without obsessive-compulsive disorder: schizophrenic and OC symptoms in schizophrenia. Journal of Clinical Psychiatry. 2003;64:1300–1307
  57. Rabe-Jablonska J. Obsessive-compulsive disorders in adolescents with diagnosed schizophrenia. Psychiatria Polska. 2001;35:47–57
  58. Ravizza L, Barzega G, Bellino S, Bogetto F, Maina G. Drug treatment of obsessive-compulsive disorder (OCD): long-term trial with clomipramine and selective serotonin reuptake inhibitors (SSRIs). Psychopharmacology Bulletin. 1996;32:167–173
  59. Reznik I, Yavin I, Stryjer R, Spivak B, Gonen N, Strous R, et al. Clozapine in the treatment of obsessive-compulsive symptoms in schizophrenia patients: a case series study. Pharmacopsychiatry. 2004;37:52–56
  60. Scheepers FE, Gespen de Wied CC, Kahn RS. The effect of olanzapine treatment on m-chlorophenylpiperazine-induced hormone release in schizophrenia. Journal of Clinical Psychopharmacology. 2001;21:575–582
  61. Schulz E, Fleischhaker C, Remschmidt HE. Correlated changes in symptoms and neurotransmitter indices during maintenance treatment with clozapine or conventional neuroleptics in adolescents and young adults with schizophrenia. Journal of Child and Adolescent Psychopharmacology. 1996;6:119–131
  62. Schulz E, Fleischhaker C, Clement HW, Remschmidt H. Blood biogenic amines during clozapine treatment of early-onset schizophrenia. Journal of Neural Transmission. 1997;104:1077–1089
  63. Stahl SM, Woo DJ, Mefford IN, Berger PA, Ciaranello RD. Hyperserotonemia and platelet serotonin uptake and release in schizophrenia and affective disorders. American Journal of Psychiatry. 1983;140:26–30
  64. Xiao R, Beck O, Hjemdahl P. On the accurate measurement of serotonin in whole blood. Scandinavian Journal of Clinical & Laboratory Investigation. 1998;58:505–510
  65. Xiao Ze-ping, Zhang Ming-dao, Wang Zhen, Chen Yu. A comparative study of platelet serotonin in patients with obsessive-compulsive disorder. Chinical Journal of Psychiatry. 2003;36:211–214
  66. Zohar J, Insel TR. Obsessive-compulsive disorder: psychobiological approaches to diagnosis, treatment, and pathophysiology. Biological Psychiatry. 1987;22:667–687

PII: S0165-1781(05)00315-X

doi: 10.1016/j.psychres.2005.10.005

Psychiatry Research
Volume 150, Issue 1 , Pages 61-69 , 28 February 2007

Article Tools

* Image Usage & Resolution